12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Proellex: Phase II started

Repros began the second cohort of 3 mg oral Proellex in a U.S. Phase II trial after a safety review of the 1 mg cohort showed that there was no liver toxicity. The trial is evaluating 1, 3,...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >